PORTLAND, Ore. , May 29, 2024 /PRNewswire/ -- Allied Market Research published a report, titled, " Radiopharmaceuticals Market by End User (Hospitals and Clinics, Medical Imaging Centers, and Others), Radioisotope (Technetium 99m , Gallium 68, Iodine I, Fluorine 18, Copper 64, Strontium 89, Yttrium 90, Radium 223, Actinium 225, Lutetium 177, Copper 67, Terbium 161, Zirconium 89, and Others), Application (Cancer, Cardiology, and Others), and Type (Diagnostic and Therapeutic): Global Opportunity Analysis and Industry Forecast, 2024-2033". According to the report, the radiopharmaceuticals market was valued at $7 .
9 billion in 2023 and is estimated to reach $21.8 billion by 2033, growing at a CAGR of 10.6% from 2024 to 2033.
Request Sample of the Report on Radiopharmaceuticals Market Forecast 2035 - https://www.alliedmarketresearch.com/request-sample/A14458 Prime determinants of growth Rise in the prevalence of chronic diseases, rise in the adoption of strategies by key players, and surge in R&D activities within the radiopharmaceuticals sector are the major factors that drive the growth of the global radiopharmaceuticals market.
However, the high cost associated with the development and implementation of radiopharmaceuticals restricts the market growth. Moreover, the rise in the number of pipeline products is expected to present new opportunities in the coming years. Report coverage & details: Report Coverage Details Forecast Period 2024–2033 Base Year 2023 Market Size In 2023.
